search
Back to results

Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Telmisartan
Enalapril
Clonidine
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 65 years
  • Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff sphygmomanometer at the end of the wash-out period
  • Written informed consent

Exclusion Criteria:

  • Secondary hypertension
  • Malignant hypertension (retinal haemorrhage, exudates or papillary oedema)
  • Clinically significant sodium depletion as defined by serum sodium level < 130 mEq/L, clinically significant hyperkaliemia as defined by serum potassium level > 5.5 mEq/L, clinically significant hypokaliemia as defined by serum potassium level < 3.0 mEq/L
  • Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm
  • Heart rate < 50 bpm
  • Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
  • Angina pectoris or myocardial infarction
  • Cardiac surgery within the past 3 months prior to start the wash-out period
  • Stroke within the past 6 months prior to start the wash-out period
  • Renal insufficiency defined as creatininaemia > 2mg/dl
  • Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant
  • Liver insufficiency, defined as bilirubinaemia > 2mg/dl and AST (aspartate aminotransferase) or ALT (alanine-aminotransferase) > twice the upper normal range
  • Clinically significant metabolic and endocrine disease
  • Autoimmune disease
  • Previous history of angioedema
  • Body mass index > 30kg/m2
  • Arm circumference > 32 cm
  • Any condition that may be likely to compromise the trial (alcohol or drug abuse, disability illness, etc.)
  • Concomitant therapy with antihypertensive drugs non-permitted by protocol, or present use of tricyclic antidepressant, corticosteroids or drugs known to affect blood pressure
  • Investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial
  • Sensitivity, significant adverse reaction or contraindications to the study drugs (telmisartan, enalapril, clonidine TTS)
  • Predictable lack of patient co-operation

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Active Comparator

    Experimental

    Active Comparator

    Arm Label

    Telmisartan

    Enalapril

    Telmisartan + clonidine TTS1

    Enalapril + clonidine TTS1

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change from baseline in 24-hours mean systolic blood pressure (SBP) (ABPM - ambulatory blood pressure measurement, 24 hours mean represents the average of 24 hourly mean values)

    Secondary Outcome Measures

    Comparison of SBP ABPM tracing profile
    Changes from baseline in trough cuff (sphygmomanometer) SBP
    Smoothness index in comparison with baseline
    Number of responders
    Number of controlled responders
    Incidence of adverse events
    Number of patients who withdraw due to adverse events

    Full Information

    First Posted
    June 26, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02177461
    Brief Title
    Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension
    Official Title
    A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2000 (undefined)
    Primary Completion Date
    August 2002 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to assess the efficacy and tolerability of Telmisartan 40-80 mg once daily compared with enalapril 10-20 mg once daily in elderly patients with arterial hypertension.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    374 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Telmisartan
    Arm Type
    Experimental
    Arm Title
    Enalapril
    Arm Type
    Active Comparator
    Arm Title
    Telmisartan + clonidine TTS1
    Arm Type
    Experimental
    Arm Title
    Enalapril + clonidine TTS1
    Arm Type
    Active Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    Enalapril
    Intervention Type
    Drug
    Intervention Name(s)
    Clonidine
    Primary Outcome Measure Information:
    Title
    Change from baseline in 24-hours mean systolic blood pressure (SBP) (ABPM - ambulatory blood pressure measurement, 24 hours mean represents the average of 24 hourly mean values)
    Time Frame
    Baseline and week 8
    Secondary Outcome Measure Information:
    Title
    Comparison of SBP ABPM tracing profile
    Time Frame
    Week 8 and 24
    Title
    Changes from baseline in trough cuff (sphygmomanometer) SBP
    Time Frame
    Baseline, week 8 and 24
    Title
    Smoothness index in comparison with baseline
    Time Frame
    Baseline, week 8 and 24
    Title
    Number of responders
    Time Frame
    Week 8 and 24
    Title
    Number of controlled responders
    Time Frame
    Week 8 and 24
    Title
    Incidence of adverse events
    Time Frame
    24 weeks
    Title
    Number of patients who withdraw due to adverse events
    Time Frame
    24 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age ≥ 65 years Sitting systolic blood pressure (SBP) ≥ 160 mmHg and any diastolic blood pressure (DBP) (safety maximum of sitting DBP 110 mmHg), measured by manual cuff sphygmomanometer at the end of the wash-out period Written informed consent Exclusion Criteria: Secondary hypertension Malignant hypertension (retinal haemorrhage, exudates or papillary oedema) Clinically significant sodium depletion as defined by serum sodium level < 130 mEq/L, clinically significant hyperkaliemia as defined by serum potassium level > 5.5 mEq/L, clinically significant hypokaliemia as defined by serum potassium level < 3.0 mEq/L Atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm Heart rate < 50 bpm Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV) Angina pectoris or myocardial infarction Cardiac surgery within the past 3 months prior to start the wash-out period Stroke within the past 6 months prior to start the wash-out period Renal insufficiency defined as creatininaemia > 2mg/dl Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post renal transplant Liver insufficiency, defined as bilirubinaemia > 2mg/dl and AST (aspartate aminotransferase) or ALT (alanine-aminotransferase) > twice the upper normal range Clinically significant metabolic and endocrine disease Autoimmune disease Previous history of angioedema Body mass index > 30kg/m2 Arm circumference > 32 cm Any condition that may be likely to compromise the trial (alcohol or drug abuse, disability illness, etc.) Concomitant therapy with antihypertensive drugs non-permitted by protocol, or present use of tricyclic antidepressant, corticosteroids or drugs known to affect blood pressure Investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial Sensitivity, significant adverse reaction or contraindications to the study drugs (telmisartan, enalapril, clonidine TTS) Predictable lack of patient co-operation

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.317_U04-1024.pdf
    Description
    Related Info

    Learn more about this trial

    Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension

    We'll reach out to this number within 24 hrs